{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:49:05Z","timestamp":1740152945689,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13048-019-0506-4","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T12:05:13Z","timestamp":1556280313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP\/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Samantha","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-6459","authenticated-orcid":false,"given":"Melissa","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dottino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Beddoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"issue":"1","key":"506_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"506_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ygyno.2016.05.020","volume":"142","author":"K Slaughter","year":"2016","unstructured":"Slaughter K, Holman LL, Thomas EL, Gunderson CC, Lauer JK, Ding K, et al. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016;142(2):225\u201330.","journal-title":"Gynecol Oncol"},{"key":"506_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ygyno.2013.11.008","volume":"132","author":"TJ Herzog","year":"2014","unstructured":"Herzog TJ, Armstrong DK, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014;132:8\u201317.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"506_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/0976-500X.136098","volume":"5","author":"R Maiti","year":"2014","unstructured":"Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5(3):186\u201392.","journal-title":"J Pharmacol Pharmacother"},{"key":"506_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"R Kerbel","year":"2004","unstructured":"Kerbel R, Karmen B. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423\u20136.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"506_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045\u20137.","journal-title":"J Clin Invest"},{"key":"506_CR7","first-page":"221","volume":"8","author":"G Klement","year":"2002","unstructured":"Klement G, Huang P, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and anti-VEGRF-2 antibody in multidrug resistant human breast cancer xenograft. Clin Cancer Res. 2002;8:221\u201332.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"506_CR8","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1001\/jamaoncol.2017.0324","volume":"3","author":"R Pramanik","year":"2017","unstructured":"Pramanik R, Agarwala S, et al. Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial. JAMA Oncol. 2017;3(9):1222\u20137.","journal-title":"JAMA Oncol"},{"issue":"5","key":"506_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1200\/JCO.2005.07.093","volume":"23","author":"K Pietras","year":"2005","unstructured":"Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose \"chemo switch\" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncology. 2005;23(5):939\u201352.","journal-title":"J Clin Oncology"},{"issue":"6","key":"506_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1634\/theoncologist.6-6-488","volume":"6","author":"P Kozuch","year":"2001","unstructured":"Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist. 2001;6(6):488\u201395.","journal-title":"Oncologist"},{"key":"506_CR11","doi-asserted-by":"crossref","unstructured":"Falcone A, Di Paolo A, et al. Sequence effect of irinotecan and fluorouracil on pharmacokinetics and toxicity in chemotherapy-na\u00efve metastatic colorectal cancer patients. J Clin Oncol 2001;19:3456\u20133462.","DOI":"10.1200\/JCO.2001.19.15.3456"},{"key":"506_CR12","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0959-8049(99)00222-1","volume":"35","author":"DR Mans","year":"1999","unstructured":"Mans DR, Grivicich I, Peters GJ, Schwartsmann G. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cells lines. Eur J Cancer. 1999;35:1851\u201361.","journal-title":"Eur J Cancer"},{"key":"506_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1023\/A:1008301522349","volume":"10","author":"CJ Moorsel van","year":"1999","unstructured":"van Moorsel CJ, Kroep JR, et al. Pharmacokinetic schedule finding of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol. 1999;10:441\u20138.","journal-title":"Ann Oncol"},{"key":"506_CR14","first-page":"5601","volume":"52","author":"T Esaki","year":"1992","unstructured":"Esaki T, Nakano S, et al. Inhibition by 5-flurouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res. 1992;52:5601\u20136506.","journal-title":"Cancer Res"},{"issue":"3","key":"506_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CAD.0b013e3280121334","volume":"18","author":"A Goel","year":"2007","unstructured":"Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, et al. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anti-Cancer Drugs. 2007;18(3):263\u201371.","journal-title":"Anti-Cancer Drugs"},{"issue":"5","key":"506_CR16","first-page":"3637","volume":"25","author":"HW Bruckner","year":"2005","unstructured":"Bruckner HW, Hrehorovich VR, Sawhney HS. Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer. Anticancer Res. 2005;25(5):3637\u20139.","journal-title":"Anticancer Res"},{"issue":"13","key":"506_CR17","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"506_CR18","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878\u201386.","journal-title":"Cancer Res"},{"issue":"1","key":"506_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/annonc\/mdf013","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13(1):73\u201380.","journal-title":"Ann Oncol"},{"issue":"1","key":"506_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","volume":"67","author":"AA Kamat","year":"2007","unstructured":"Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007;67(1):281\u20138.","journal-title":"Cancer Res"},{"key":"506_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2407-7-65","volume":"7","author":"R Samaritani","year":"2007","unstructured":"Samaritani R, Corrado G, Vizza E, Sbiroli C. Cyclophosphamide \"metronomic\" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer. 2007;7:65.","journal-title":"BMC Cancer"},{"issue":"12","key":"506_CR22","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1158\/1535-7163.MCT-14-0630","volume":"14","author":"RA Previs","year":"2015","unstructured":"Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, et al. Dual metronomic chemotherapy with nab-paclitaxel and Topotecan has potent antiangiogenic activity in ovarian Cancer. Mol Cancer Ther. 2015;14(12):2677\u201386.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"506_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia. J Clin Oncol. 2008;26(1):76\u201382.","journal-title":"J Clin Oncol"},{"issue":"3","key":"506_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00001813-200403000-00004","volume":"15","author":"R Rachamalla","year":"2004","unstructured":"Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil\/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anti-Cancer Drugs. 2004;15(3):211\u20137.","journal-title":"Anti-Cancer Drugs"},{"key":"506_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00000421-199810000-00018","volume":"21","author":"S Kakolyris","year":"1998","unstructured":"Kakolyris S, Samonis G, et al. Treatment of non-small-cell- lung cancer with prolonged oral etoposide. Am J Clin Oncol. 1998;21:505\u20138.","journal-title":"Am J Clin Oncol"},{"key":"506_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/01.cad.0000224454.46824.fc","volume":"17","author":"L Orlando","year":"2006","unstructured":"Orlando L, Cardillo A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs. 2006;17:961\u20137.","journal-title":"Anti-Cancer Drugs"},{"key":"506_CR27","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1186\/1471-2407-14-947","volume":"14","author":"G Ferrandina","year":"2014","unstructured":"Ferrandina G, Corrado G, Mascilini F, Malaguti P, Samaritani R, Distefano M, et al. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study. BMC Cancer. 2014;14:947.","journal-title":"BMC Cancer"},{"key":"506_CR28","doi-asserted-by":"crossref","unstructured":"Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, et al. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - results of the PACOVAR-trial. Gynecol Oncol. 2017.","DOI":"10.1016\/j.ygyno.2017.05.013"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0506-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0506-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:20:14Z","timestamp":1587684014000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0506-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0506-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2019,4,25]]},"assertion":[{"value":"31 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained for this retrospective study via the Icahn School of Medicine Institutional Review Board (IRB-16-00857).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"36"}}